Characteristics of pericardial effusions in patients with leukemia.
BACKGROUND
Little information exists regarding the prevalence and natural history of pericardial disease in patients with leukemia. Recently, it has been reported that the use of histone deacetylase inhibitors is associated with an increased incidence of pericardial effusions (PEs). To study the characteristics and treatment relationships of PEs in patients with leukemia, the authors retrospectively analyzed a cohort of patients with leukemia evaluated at a single center.


METHODS
The authors reviewed 2592 patients with acute myeloid leukemia (AML, n = 1282, 49%), acute lymphocytic leukemia (ALL, n = 336, 13%), or myelodysplastic syndrome (MDS, n = 974, 38%), who were evaluated from August 2003 to July 2008. Electronic medical records were reviewed to select patients who had undergone at least 1 echocardiographic evaluation. Data regarding diagnosis, timing, effusion size, survival, and prior therapy were collected for the patients who had echocardiographic evidence of PEs.


RESULTS
PEs were detected in 325 (20%) of the patients who had echocardiograms: 21% in AML, 23% in ALL, and 18% in MDS patients. Only a small portion of PEs were detected before the initiation of therapy: 26% in AML, 25% ALL, and 15% in MDS patients. Most PEs were of minimal size (70%) overall. No significant differences in effusion characteristics, including severity, were observed among different types of therapies. The presence of PEs had no impact on the survival of the patients evaluated.


CONCLUSIONS
PEs are relatively common in patients with leukemia and do not appear to be related to specific types of therapy or to survival.
Sampat
Keeran
K
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Rossi
Adriana
A
Garcia-Gutierrez
Valentin
V
Cortes
Jorge
J
Pierce
Sherry
S
Kantarjian
Hagop
H
Garcia-Manero
Guillermo
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects; D001201:Ascites / Q000150:complications; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects; D006801:Humans; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010490:Pericardial Effusion / Q000150:complications* / Q000209:etiology; D010996:Pleural Effusion / Q000150:complications
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors